Semiconductor Sequencing for Preimplantation Genetic Testing for Aneuploidy
August 25th, 2019
9K views
Here, we introduce a semiconductor sequencing method for preimplantation genetic testing for aneuploidy (PGT-A) with the advantages of short turnaround time, low cost, and high throughput.
Overview
This article presents a semiconductor sequencing method for preimplantation genetic testing for aneuploidy (PGT-A). The method is characterized by a short turnaround time, low cost, and high throughput.
Key Study Components
Area of Science
- Genetics
- Embryology
- Sequencing Technology
Background
- Preimplantation genetic testing is crucial for identifying aneuploid embryos.
- Traditional methods can be time-consuming and expensive.
- Advancements in sequencing technology have enabled faster and more efficient testing.
- This study focuses on a novel semiconductor sequencing approach.
Purpose of Study
- To introduce a rapid and cost-effective method for PGT-A.
- To improve the efficiency of aneuploidy screening in embryos.
- To reduce the turnaround time for genetic testing results.
Methods Used
- Semiconductor sequencing technology for template amplification.
- Library preparation optimized for high throughput.
- Rapid sequencing with a runtime of 2-4 hours.
- Streamlined process from sample receipt to report issuance within five days.
Main Results
- The method provides reliable genome sequencing for aneuploidy screening.
- It allows for the detection of copy number variations and single nucleotide polymorphisms.
- The approach is reproducible and cost-efficient.
- Library prepared cannot be sequenced on other systems due to specific chemistry.
Conclusions
- This semiconductor sequencing method enhances PGT-A efficiency.
- It offers a viable alternative to traditional genetic testing methods.
- The reduced turnaround time benefits clinical applications in reproductive health.
Frequently Asked Questions
What is preimplantation genetic testing for aneuploidy?
It is a genetic test performed on embryos to identify chromosomal abnormalities before implantation.
How does semiconductor sequencing work?
It uses semiconductor technology to detect changes in pH that occur during DNA sequencing.
What are the advantages of this method?
The method is rapid, cost-effective, and allows for high throughput screening.
How long does the sequencing process take?
The sequencing runtime is between 2 to 4 hours.
What is the turnaround time for results?
Results can be issued within five days from sample receipt.
Can the library prepared be used on other sequencing systems?
No, the library prepared by this protocol cannot be sequenced directly on other systems due to different sequencing chemistry.
Executive Industry Relevance
Semiconductor sequencing enables rapid, cost-effective detection of chromosomal aneuploidies in embryos, directly supporting preimplantation genetic testing for aneuploidy (PGT-A) workflows. The method reduces turnaround time from sample receipt to report issuance to five days, improving clinical decision-making in reproductive health. Its high-throughput capacity (24 samples per chip) and reproducibility enhance scalability for IVF clinics and research laboratories.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of chromosomal integrity as a biomarker for embryonic viability and developmental potential.
- Operational Value: Provides quantitative copy number variation data to de-risk hypotheses about genomic stability in early-stage models.
Screening & Assay Development
- Scientific Value: Generates genome-wide sequencing data for aneuploidy screening with >95% whole genome amplification success rates.
- Operational Value: Delivers standardized library preparation and sequencing protocols ensuring reproducibility across batches.
Translational & Preclinical Research
- Scientific Value: Supports analysis of chromosomal mosaicism and copy number variations <5 Mb in human embryos, informing preclinical models of genomic instability.
- Operational Value: Enables continuous monitoring of genomic integrity from discovery through preclinical validation stages.
Pipeline & Workflow Integration
The method integrates into early discovery workflows by providing genomic quality control for embryonic models prior to downstream applications.
- Discovery Biology: Facilitates hypothesis testing regarding chromosomal abnormalities as drivers of developmental arrest or implantation failure.
- Screening: Enables high-throughput, reproducible aneuploidy screening with quantitative sequencing outputs.
- Analytics: Supports copy number variation and single nucleotide polymorphism calling for genomic stability assessment.
- Translational Research: Connects embryonic genomic screening to preclinical continuity through chromosomal biomarker alignment.
- Enterprise Reuse: Establishes a reusable genomic QC platform applicable across stem cell, organoid, and embryo-based models.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in embryonic model selection through direct aneuploidy detection.
- Operational Value: Standardized, high-throughput workflow with 2-4 hour sequencing runtime and 5-day turnaround.
- Strategic Value: Reduces biological risk in preclinical models by enabling early exclusion of chromosomally abnormal samples.
- Portfolio Impact: Supports risk-adjusted prioritization of embryonic models based on genomic integrity metrics.
Implementation Considerations
- Requires expertise in whole genome amplification and semiconductor sequencing library preparation.
- Dependent on Ion Torrent semiconductor sequencer and proprietary chemistry.
- Necessitates cross-team standardization for library pooling and template preparation.
- Limited to semiconductor sequencing platforms due to library chemistry constraints.
- Practical limitation: Library cannot be sequenced on other NGS systems due to specialized preparation.
Biopharma FAQs
Why does whole genome amplification success rate matter for target validation?
The method achieves over 95% WGA success in both cleavage stage and blastocyst embryos, ensuring reliable input material for downstream aneuploidy detection and reducing false negatives in genomic screening.
How does semiconductor sequencing runtime fit the discovery pipeline?
With a sequencing runtime of only 2-4 hours, the method enables rapid genomic quality control of embryonic models, fitting within early discovery timelines for hypothesis testing and model selection.
What quantitative dependent variable measurements enable aneuploidy calling?
The sequencing data provides copy number variation measurements and single nucleotide polymorphism calls, which are used to detect chromosomal abnormalities such as trisomies and monosomies in embryos.
Why do replication requirements matter for cross-functional collaboration?
The method’s reproducibility, demonstrated by low sequencing quality control failure rates (3.4% in cleavage stage, 1.9% in blastocyst), ensures consistent results across teams and sites, supporting reliable data sharing in collaborative projects.
What statistical analysis capabilities are required before implementation?
Implementation requires capability to analyze sequencing depth, quality scores, and copy number variation thresholds, as demonstrated by the retrospective statistical analysis on 186 cleavage stage and 1135 blastocyst embryos to establish performance benchmarks.
